Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Armata Pharmaceuticals, Inc. (ARMP)
USD3.99
+0.07 (+1.66%)
US AMEX Healthcare Biotechnology
Address
4503 Glencoe Avenue 90292
Marina del Rey, CA, US
Marina del Rey, CA, US
CEO
Deborah L. Birx
Website
armatapharma.com
IPO
1994-05-20
CIK 921114 ISIN US04216R1023
Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.99
+0.07 (+1.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
107.9K
Beta
1.23
Float Shares
11.27M
Free Float %
30.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.04% | -1.85% | -19.06% | +9.22% | +34.53% | +43.31% | +592.31% | +620.00% | +124.44% | -96.69% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
3.99
Low
15.00
+276.4%
Consensus
15.00
+276.4%
Median
15.00
+276.4%
High
15.00
+276.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
15.00
+276.4%
|
| Last Year | 2 |
12.00
+201.1%
|
| All Time | 2 |
12.00
+201.1%
|
Quality scores
Altman Z-Score
-9.76
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-5.2% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-823.1% Q1'26: -1,655.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-983.6%
-
EBIT margin Biotechnology: +0.0%-636.7%
-
ROIC Biotechnology: -16.1%-51.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.2% ★ Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-9.70×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
18.88M
est: 17.79M (+6.1%)
|
475.0K
est: 495.0K (-4.0%)
|
260.0K
est: 300.0K (-13.3%)
|
115.0K
est: 100.0K (+15.0%)
|
823.0K
est: 359.5K (+128.9%)
|
4.47M
est: 4.40M (+1.7%)
|
5.51M
est: 6.15M (-10.4%)
|
4.53M
est: 4.70M (-3.6%)
|
5.17M
est: 5.50M (-5.9%)
|
4.90M
est: 4.55M (+7.8%)
|
5.08M
5.08M – 5.08M
+11.6% YoY
|
6.09M
6.09M – 6.09M
+19.9% YoY
|
56.29M
56.29M – 56.29M
+824.4% YoY
|
19.00M
19.00M – 19.00M
-66.2% YoY
|
56.50M
56.50M – 56.50M
+197.4% YoY
|
| EBITDA |
-19.91M
est: -17.26M (-15.3%)
|
-10.23M
est: -495.0K (-1,966.1%)
|
-13.46M
est: -300.0K (-4,387.3%)
|
-9.98M
est: -100.0K (-9,882.0%)
|
-20.44M
est: -359.5K (-5,585.4%)
|
-21.92M
est: -4.40M (-398.2%)
|
-36.05M
est: -6.15M (-486.2%)
|
-65.45M
est: -4.70M (-1,292.8%)
|
-41.11M
est: -5.50M (-647.5%)
|
-29.69M
est: -4.55M (-552.5%)
|
-5.08M
-5.08M – -5.08M
-11.6% YoY
|
-6.09M
-6.09M – -6.09M
-19.9% YoY
|
-56.29M
-56.29M – -56.29M
-824.4% YoY
|
-19.00M
-19.00M – -19.00M
+66.2% YoY
|
-56.50M
-56.50M – -56.50M
-197.4% YoY
|
| EBIT |
-28.60M
est: -9.93M (-188.2%)
|
-10.23M
est: -495.0K (-1,966.1%)
|
-13.83M
est: -300.0K (-4,510.3%)
|
-10.36M
est: -100.0K (-10,256.0%)
|
-21.55M
est: -359.5K (-5,895.3%)
|
-23.09M
est: -4.40M (-424.8%)
|
-36.95M
est: -6.15M (-500.7%)
|
-66.42M
est: -4.70M (-1,313.5%)
|
-42.44M
est: -5.50M (-671.6%)
|
-31.22M
est: -4.55M (-586.2%)
|
-5.08M
-5.08M – -5.08M
-11.6% YoY
|
-6.09M
-6.09M – -6.09M
-19.9% YoY
|
-56.29M
-56.29M – -56.29M
-824.4% YoY
|
-19.00M
-19.00M – -19.00M
+66.2% YoY
|
-56.50M
-56.50M – -56.50M
-197.4% YoY
|
| Net Income |
-27.17M
est: -26.39M (-3.0%)
|
-516.0K
est: -8.94B (+100.0%)
|
-18.84M
est: -5.52B (+99.7%)
|
-12.84M
est: -1.10B (+98.8%)
|
-22.18M
est: -41.04M (+46.0%)
|
-23.16M
est: -31.94M (+27.5%)
|
-36.92M
est: -30.38M (-21.5%)
|
-69.05M
est: -79.89M (+13.6%)
|
-18.92M
est: -34.43M (+45.1%)
|
-173.80M
est: -59.25M (-193.3%)
|
-41.68M
-41.68M – -41.68M
+29.7% YoY
|
-33.70M
-33.70M – -33.70M
+19.1% YoY
|
-34.43M
-34.43M – -34.43M
-2.2% YoY
|
-20.29M
-20.29M – -20.29M
+41.1% YoY
|
-3.62M
-3.62M – -3.62M
+82.1% YoY
|
| SGA |
6.20M
est: 6.35M (-2.2%)
|
6.42M
est: 1.76M (+264.7%)
|
8.41M
est: 1.07M (+688.4%)
|
7.59M
est: 355.7K (+2,033.7%)
|
7.97M
est: 1.28M (+522.9%)
|
8.28M
est: 15.65M (-47.1%)
|
7.44M
est: 21.88M (-66.0%)
|
10.68M
est: 10.00M (+6.8%)
|
13.18M
est: 11.70M (+12.7%)
|
12.41M
est: 9.68M (+28.2%)
|
10.81M
10.81M – 10.81M
+11.6% YoY
|
12.96M
12.96M – 12.96M
+19.9% YoY
|
119.76M
119.76M – 119.76M
+824.4% YoY
|
40.42M
40.42M – 40.42M
-66.2% YoY
|
120.20M
120.20M – 120.20M
+197.4% YoY
|
| EPS |
-3,100.00
est: -41,533.34 (+92.5%)
|
-278.60
est: -247.10 (-12.7%)
|
-345.80
est: -152.60 (-126.6%)
|
-28.14
est: -30.38 (+7.4%)
|
-1.35
est: -1.14 (-18.9%)
|
-0.96
est: -0.88 (-8.7%)
|
-1.08
est: -0.84 (-28.6%)
|
-1.91
est: -2.20 (+13.4%)
|
-0.52
est: -0.95 (+45.3%)
|
-4.80
est: -1.64 (-193.6%)
|
-1.15
-1.15 – -1.15
+29.7% YoY
|
-0.93
-0.93 – -0.93
+19.1% YoY
|
-0.95
-0.95 – -0.95
-2.2% YoY
|
-0.56
-0.56 – -0.56
+41.1% YoY
|
-0.10
-0.10 – -0.10
+82.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-59.48M
OE per share TTM
-1.64
Owner's Yield
-18.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,023.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
758.6K
Insider transactions (90d)
1
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Innoviva, Inc. | 44.44M | 80.10% | 17.42M | 27.02M | 17.42M | 10.00 | CO | — | 2022-04-01 | ↗ |
| 2 | Innoviva Strategic Opportunities LLC | 27.02M | 48.70% | — | 27.02M | — | 10.00 | OO | — | 2022-04-01 | ↗ |
| 3 | Peter Kolchinsky | 26.79M | 9.70% | — | 26.79M | — | 26.79M | IN | States | 2015-02-17 | ↗ |
| 4 | RA Capital Management, LLC | 26.79M | 9.70% | — | 26.79M | — | 26.79M | IA | Massachusetts | 2015-02-17 | ↗ |
| 5 | Anthony M. Smithyman | 25.37M | 9.13% | 11.89M | 11.48M | 11.89M | 11.48M | IN | Australia | 2015-04-27 | ↗ |
| 6 | L.P. | 21.43M | 7.80% | — | 21.43M | — | 21.43M | PN | Delaware | 2015-02-17 | ↗ |
| 7 | Broadfin Capital, LLC | 14.00M | 7.67% | — | 14.00M | — | 14.00M | OO | Delaware | 2014-01-03 | ↗ |
| 8 | Broadfin Healthcare Master Fund, Ltd. | 14.00M | 7.67% | — | 14.00M | — | 14.00M | CO | Delaware | 2014-01-03 | ↗ |
| 9 | Kevin Kotler | 14.00M | 7.67% | — | 14.00M | — | 14.00M | HC, IN | Delaware | 2014-01-03 | ↗ |
| 10 | BANK OF AMERICA CORPORATION | 5.57M | 11.90% | — | 354.6K | — | 354.6K | HC | Cayman Islands | 2016-06-02 | ↗ |
| 11 | 51-0346580 | 2.56M | 7.00% | 2.56M | — | 2.56M | — | CO | Washington | 2000-08-28 | ↗ |
| 12 | (: 04-3002117 | 2.17M | 19.90% | — | 2.17M | — | 10.00 | CO | Massachusetts | 2006-11-09 | ↗ |
| 13 | (: 33-0112644 | 2.17M | 19.90% | — | 2.17M | — | 10.00 | CO | Delaware | 2006-11-09 | ↗ |
| 14 | Prensky | 1.74M | 7.90% | 780.0K | 955.0K | 780.0K | — | IN | Delaware | 2010-06-11 | ↗ |
| 15 | 39-6006423 | 1.66M | 4.99% | 1.66M | — | 1.66M | — | EP | Madison, Wisconsin | 2000-02-09 | ↗ |
| 16 | Empery Asset Management, LP | 1.32M | 3.92% | — | 1.32M | — | — | PN | Delaware | 2019-01-10 | ↗ |
| 17 | Martin D. Hoe | 1.32M | 3.92% | — | 1.32M | — | — | IN | Delaware | 2019-01-10 | ↗ |
| 18 | Ryan M. Lane | 1.32M | 3.92% | — | 1.32M | — | — | IN | Delaware | 2019-01-10 | ↗ |
| 19 | Delta Dental Plan of Michigan, Inc. | 1.27M | 12.70% | — | 1.27M | — | 1.27M | CO | Michigan | 2019-05-17 | ↗ |
| 20 | Renaissance Holding Company | 1.27M | 12.70% | — | 1.27M | — | 1.27M | CO | Michigan | 2019-05-17 | ↗ |
| 21 | Hudson Bay Capital Management, L.P. | 1.24M | 6.90% | — | 1.24M | — | 1.24M | PN | Delaware | 2017-01-30 | ↗ |
| 22 | Mann | 980.0K | 4.40% | 25.0K | 955.0K | 25.0K | — | IN | Delaware | 2010-06-11 | ↗ |
| 23 | Trading LLC (80-0308646) | 955.0K | 4.30% | — | 955.0K | — | — | OO | Delaware | 2010-06-11 | ↗ |
| 24 | Corvesta, Inc. | 633.9K | 6.40% | 633.9K | — | 633.9K | — | CO | Virginia | 2019-05-21 | ↗ |
| 25 | Inc. | 517.0K | 5.20% | 517.0K | — | 517.0K | 517.0K | CO | Delaware | 2019-11-12 | ↗ |
| 26 | Hudson Bay Capital Management LP | 498.9K | 4.99% | — | 498.9K | — | — | PN | State of Delaware | 2019-01-30 | ↗ |
| 27 | Sander Gerber | 498.9K | 4.99% | — | 498.9K | — | — | IN | State of Delaware | 2019-01-30 | ↗ |
| 28 | Armistice Capital Master Fund Ltd. | — | 0.00% | — | — | — | — | CO | Delaware | 2018-03-29 | ↗ |
| 29 | Armistice Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2018-03-29 | ↗ |
| 30 | Steven Boyd | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2018-03-29 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-27 vs prev Q
New positions
1
Closed positions
28
Increased
2
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 357.6K +60.6K (+20.4%) | 2.25M +1.4M (+153.7%) | 0.99% +0.167 pp | 0.00% +0.000 pp | USD3.56 +76.4% | 27 qtrs — |
| 2 | 683 CAPITAL MANAGEMENT, LLC | 139.9K +139.9K (+100.0%) | 878.3K +878.3K (+100.0%) | 0.39% +0.386 pp | 0.04% +0.038 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 109.9K +5.3K (+5.1%) | 690.3K +378.6K (+121.5%) | 0.30% +0.015 pp | 0.00% +0.000 pp | USD3.50 +79.4% | 20 qtrs — |
| 4 | EDGEWOOD MANAGEMENT LLC | 100.0K +— (+0.0%) | 628.0K +330.0K (+110.7%) | 0.28% 0.000 pp | 0.00% +0.002 pp | USD4.49 +39.9% | 25 qtrs — |
| 5 | BLACKROCK, INC. | 72.8K +46.1K (+172.9%) | 457.0K +377.5K (+475.1%) | 0.20% +0.127 pp | 0.00% +0.000 pp | USD4.84 +29.8% | 6 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 68.5K +27.2K (+65.9%) | 430.2K +307.1K (+249.5%) | 0.19% +0.075 pp | 0.00% +0.001 pp | USD4.73 +32.8% | 27 qtrs — |
| 7 | STATE STREET CORP | 50.8K +10.5K (+26.1%) | 319.0K +198.9K (+165.6%) | 0.14% +0.029 pp | 0.00% +0.000 pp | USD3.68 +70.7% | 10 qtrs — |
| 8 | GOLDMAN SACHS GROUP INC | 45.2K +45.2K (+100.0%) | 283.6K +283.6K (+100.0%) | 0.12% +0.125 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 9 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 44.7K +— (+0.0%) | 280.6K +147.5K (+110.7%) | 0.12% 0.000 pp | 0.01% +0.003 pp | USD3.02 +107.9% | 20 qtrs — |
| 10 | SEACREST WEALTH MANAGEMENT, LLC | 41.0K +6.0K (+17.3%) | 273.8K +161.2K (+143.3%) | 0.11% +0.017 pp | 0.03% +0.016 pp | USD4.00 +57.0% | 24 qtrs — |
| 11 | GSB WEALTH MANAGEMENT, LLC | 30.0K +— (+0.0%) | 188.4K +99.0K (+110.7%) | 0.08% 0.000 pp | 0.04% +0.022 pp | USD1.90 +230.5% | 3 qtrs — |
| 12 | OMERS ADMINISTRATION CORP | 28.1K +28.1K (+100.0%) | 176.6K +176.6K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.001 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 13 | MILLENNIUM MANAGEMENT LLC | 26.1K +26.1K (+100.0%) | 163.8K +163.8K (+100.0%) | 0.07% +0.072 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 14 | NORTHERN TRUST CORP | 24.6K +5.4K (+27.9%) | 154.8K +97.3K (+169.5%) | 0.07% +0.015 pp | 0.00% +0.000 pp | USD5.19 +21.0% | 16 qtrs — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 24.4K +24.4K (+100.0%) | 153.0K +153.0K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 16 | QUBE RESEARCH & TECHNOLOGIES LTD | 23.4K +23.4K (+100.0%) | 146.7K +146.7K (+100.0%) | 0.06% +0.065 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 17 | JANE STREET GROUP, LLC | 17.2K +17.2K (+100.0%) | 107.7K +107.7K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 18 | CAPTRUST FINANCIAL ADVISORS | 13.1K +— (+0.0%) | 82.5K +43.4K (+110.7%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD1.67 +276.0% | 12 qtrs — |
| 19 | CITADEL ADVISORS LLC | 10.8K +10.8K (+100.0%) | 67.7K +67.7K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 20 | DAUNTLESS INVESTMENT GROUP, LLC | 6.1K +6.1K (+100.0%) | 38.5K +38.5K (+100.0%) | 0.02% +0.017 pp | 0.03% +0.031 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 21 | BANK OF AMERICA CORP /DE/ | 3.5K +3.5K (+50,128.6%) | 22.1K +22.1K (+105,042.9%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD6.27 +0.2% | 26 qtrs — |
| 22 | MORGAN STANLEY | 2.3K +2.3K (+113,350.0%) | 14.3K +14.2K (+237,400.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 27 qtrs — |
| 23 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.6K +1.2K (+351.8%) | 10.1K +9.0K (+852.1%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD5.37 +16.9% | 15 qtrs — |
| 24 | — | 1.4K +— (+0.0%) | 9.0K +4.7K (+110.8%) | 0.00% +0.000 pp | 0.00% +0.002 pp | USD2.37 +165.0% | 6 qtrs — |
| 25 | UBS GROUP AG | 1.0K +977.0 (+2,220.5%) | 6.4K +6.3K (+4,794.7%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD6.14 +2.3% | 27 qtrs — |
| 26 | MEASURED WEALTH PRIVATE CLIENT GROUP, LLC | 1.0K +— (+0.0%) | 6.3K +3.3K (+110.7%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD2.98 +110.7% | 2 qtrs — |
| 27 | TRIFECTA CAPITAL ADVISORS, LLC | 714.00 +— (+0.0%) | 4.5K +2.4K (+110.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.24 +406.5% | 13 qtrs — |
| 28 | BNP PARIBAS ARBITRAGE, SNC | 710.00 +710.0 (+100.0%) | 4.5K +4.5K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 29 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 571.00 +— (+0.0%) | 3.6K +1.9K (+110.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.75 +67.5% | 27 qtrs — |
| 30 | ADVISOR GROUP HOLDINGS, INC. | 357.00 -100.0 (-21.9%) | 2.2K +880.0 (+64.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.55 +305.2% | 4 qtrs — |
| 31 | WHITTIER TRUST CO | 100.00 +100.0 (+100.0%) | 587.00 +587.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.28 +0.0% | 1 qtrs NEW |
| 32 | GENEOS WEALTH MANAGEMENT INC. | 92.00 +92.0 (+100.0%) | 578.00 +578.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.27 +0.2% | 1 qtrs NEW |
| 33 | MAI CAPITAL MANAGEMENT | 71.00 +— (+0.0%) | 446.00 +234.0 (+110.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.85 +239.5% | 5 qtrs — |
| 34 | TEAM FINANCIAL GROUP, LLC | 71.00 +— (+0.0%) | 446.00 +234.0 (+110.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.89 +232.3% | 3 qtrs — |
| 35 | SBI SECURITIES CO., LTD. | 3.00 +— (+0.0%) | 19.00 +10.0 (+111.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.67 +276.0% | 5 qtrs — |
| 36 | WELLS FARGO & COMPANY/MN | 1.00 +— (+0.0%) | 3.00 +2.0 (+200.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +528.0% | 13 qtrs — |
| 37 | JPMORGAN CHASE & CO | — -24.0 (-100.0%) | — -72.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 38 | SALEM INVESTMENT COUNSELORS INC | — -100.0 (-100.0%) | — -298.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 39 | BARCLAYS PLC | — -6.0 (-100.0%) | — -18.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 40 | GROUP ONE TRADING, L.P. | — -3.0K (-100.0%) | — -8.9K (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 33 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 169.3K | 0.60% |
| 2 | iShares Russell 2000 Growth ETF IWO | 0.00% | 475.6K | 0.24% |
| 3 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 69.5K | 0.30% |
| 4 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 5.1K | 0.25% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.00% | 23.6K | 0.08% |
| 6 | Vanguard Extended Market ETF VXF | 0.00% | 1.01M | 0.05% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 587.46 | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 856.5K | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 5.6K | 0.36% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 2.0K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
9
Sells
0
Shares acquired
691.1K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+691,058
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | Gilmer Daniel B. | Director | A-Award | A | Stock Options (Right to Buy) | 51,280 | 12.92 | 662.5K | 51,280 | D | ↗ |
| 2026-03-14 | Kyme Pierre | Officer | F-InKind | D | Common Stock | 1,030 | 10.54 | 10.9K | 9,461 | D | ↗ |
| 2026-03-14 | Birx Deborah | Director / Officer | F-InKind | D | Common Stock | 4,919 | 10.54 | 51.8K | 212,458 | D | ↗ |
| 2026-03-09 | Schlesinger Sarah J. | Director | A-Award | A | Stock Options (Right to Buy) | 25,640 | 11.61 | 297.7K | 25,640 | D | ↗ |
| 2026-03-09 | Peterson Todd C. | Director | A-Award | A | Stock Options (Right to Buy) | 25,640 | 11.61 | 297.7K | 25,640 | D | ↗ |
| 2026-03-09 | PATTI JOSEPH M | Director | A-Award | A | Stock Options (Right to Buy) | 25,640 | 11.61 | 297.7K | 25,640 | D | ↗ |
| 2026-03-09 | Odysseas Kostas D | Director | A-Award | A | Stock Options (Right to Buy) | 25,640 | 11.61 | 297.7K | 25,640 | D | ↗ |
| 2026-03-09 | Kyme Pierre | Officer | A-Award | A | Stock Options (Right to Buy) | 183,142 | 11.61 | 2.13M | 183,142 | D | ↗ |
| 2026-03-09 | Kramer Robin | Director | A-Award | A | Stock Options (Right to Buy) | 25,640 | 11.61 | 297.7K | 25,640 | D | ↗ |
| 2026-03-09 | House David Duane | Officer | A-Award | A | Stock Options (Right to Buy) | 109,885 | 11.61 | 1.28M | 109,885 | D | ↗ |
| 2026-03-09 | Haimovitz Jules | Director | A-Award | A | Stock Options (Right to Buy) | 25,640 | 11.61 | 297.7K | 25,640 | D | ↗ |
| 2026-03-09 | Birx Deborah | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 421,226 | 11.61 | 4.89M | 421,226 | D | ↗ |
| 2025-07-10 | Birx Deborah | Director / Officer | F-InKind | D | Common Stock | 13,637 | 2.27 | 31.0K | 217,377 | D | ↗ |
| 2025-03-14 | Kyme Pierre | Officer | F-InKind | D | Common Stock | 1,027 | 1.95 | 2.0K | 10,491 | D | ↗ |
| 2025-03-14 | Birx Deborah | Director / Officer | F-InKind | D | Common Stock | 6,061 | 1.95 | 11.8K | 231,014 | D | ↗ |
| 2025-02-05 | Schlesinger Sarah J. | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 2.04 | 110.9K | 54,343 | D | ↗ |
| 2025-02-05 | Peterson Todd C. | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 2.04 | 110.9K | 54,343 | D | ↗ |
| 2025-02-05 | PATTI JOSEPH M | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 2.04 | 110.9K | 54,343 | D | ↗ |
| 2025-02-05 | Odysseas Kostas D | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 2.04 | 110.9K | 54,343 | D | ↗ |
| 2025-02-05 | Kyme Pierre | Officer | A-Award | A | Stock Options (Right to Buy) | 100,000 | 2.04 | 204.0K | 100,000 | D | ↗ |
| 2025-02-05 | Kramer Robin | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 2.04 | 110.9K | 54,343 | D | ↗ |
| 2025-02-05 | House David Duane | Officer | A-Award | A | Stock Options (Right to Buy) | 25,000 | 2.04 | 51.0K | 25,000 | D | ↗ |
| 2025-02-05 | Haimovitz Jules | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 2.04 | 110.9K | 54,343 | D | ↗ |
| 2025-02-05 | Birx Deborah | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 240,000 | 2.04 | 489.6K | 240,000 | D | ↗ |
| 2024-10-02 | House David Duane | Officer | A-Award | A | Stock Options (Right to Buy) | 75,000 | 2.32 | 174.0K | 75,000 | D | ↗ |
| 2024-08-16 | House David Duane | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-10 | Birx Deborah | Director / Officer | F-InKind | D | Common Stock | 22,925 | 2.68 | 61.4K | 237,075 | D | ↗ |
| 2024-06-19 | Kyme Pierre | Officer | — | — | Stock Options (Right to Buy) | 22,000 | 3.15 | 69.3K | 0 | D | ↗ |
| 2024-03-14 | Schlesinger Sarah J. | Director | A-Award | A | Stock Options (Right to Buy) | 54,343 | 3.38 | 183.7K | 94,009 | — | ↗ |
| 2024-03-14 | Rychlik Richard | Officer | A-Award | A | Stock Options (Right to Buy) | 40,000 | 3.38 | 135.2K | 40,000 | — | ↗ |
| 2024-03-14 | Peterson Todd C. | Director | A-Award | A | Stock Options (Right to Buy) | 39,666 | 3.38 | 134.1K | 39,666 | — | ↗ |
| 2024-03-14 | PATTI JOSEPH M | Director | A-Award | A | Stock Options (Right to Buy) | 39,666 | 3.38 | 134.1K | 39,666 | — | ↗ |
| 2024-03-14 | Odysseas Kostas D | Director | A-Award | A | Stock Options (Right to Buy) | 39,666 | 3.38 | 134.1K | 39,666 | — | ↗ |
| 2024-03-14 | Kramer Robin | Director | A-Award | A | Stock Options (Right to Buy) | 39,666 | 3.38 | 134.1K | 39,666 | — | ↗ |
| 2024-03-14 | Haimovitz Jules | Director | A-Award | A | Stock Options (Right to Buy) | 39,666 | 3.38 | 134.1K | 39,666 | — | ↗ |
| 2024-03-14 | Birx Deborah | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 240,000 | 3.38 | 811.2K | 240,000 | — | ↗ |
| 2023-12-21 | Schlesinger Sarah J. | Director | A-Award | A | Stock Options (Right to Buy) | 10,461 | 2.39 | 25.0K | 10,461 | — | ↗ |
| 2023-12-21 | Rychlik Richard | Officer | A-Award | A | Stock Options (Right to Buy) | 50,000 | 2.39 | 119.5K | 50,000 | — | ↗ |
| 2023-12-21 | Peterson Todd C. | Director | A-Award | A | Stock Options (Right to Buy) | 10,461 | 2.39 | 25.0K | 10,461 | — | ↗ |
| 2023-12-21 | PATTI JOSEPH M | Director | A-Award | A | Stock Options (Right to Buy) | 10,461 | 2.39 | 25.0K | 10,461 | — | ↗ |
| 2023-12-21 | Odysseas Kostas D | Director | A-Award | A | Stock Options (Right to Buy) | 10,461 | 2.39 | 25.0K | 10,461 | — | ↗ |
| 2023-12-21 | Kramer Robin | Director | A-Award | A | Stock Options (Right to Buy) | 10,461 | 2.39 | 25.0K | 10,461 | — | ↗ |
| 2023-12-21 | Haimovitz Jules | Director | A-Award | A | Stock Options (Right to Buy) | 10,461 | 2.39 | 25.0K | 10,461 | — | ↗ |
| 2023-12-21 | Birx Deborah | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 200,000 | 2.39 | 478.0K | 200,000 | — | ↗ |
| 2023-09-15 | Rychlik Richard | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-10 | Birx Deborah | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-02 | Averill Julianne | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-10 | Innoviva, Inc. | Director | P-Purchase | A | Convertible Debt convertible into Common Stock | 0 | 30,000,000.00 | — | 0 | — | ↗ |
| 2022-07-01 | Butler Erin | Officer | — | D | Stock Option (Right to Buy) | 50,000 | 5.11 | 255.5K | 0 | — | ↗ |
| 2022-04-13 | Varnum Brian | Officer | A-Award | A | Stock Options (Right to Buy) | 240,000 | 0.00 | — | 240,000 | — | ↗ |
| 2022-04-13 | Schlesinger Sarah J. | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-04-13 | Peterson Todd C. | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 5.11 | 168.6K | 33,000 | — | ↗ |
| 2022-04-13 | Patrick Todd | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-04-13 | PATTI JOSEPH M | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-04-13 | Odysseas Kostas D | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-04-13 | Morris Duane Alfred | Officer | A-Award | A | Stock Options (Right to Buy) | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-04-13 | Kramer Robin | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-04-13 | Haimovitz Jules | Director | A-Award | A | Stock Options (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-03-31 | Innoviva Strategic Opportunities LLC | Director | P-Purchase | A | Common Stock | 5,385,208 | 5.00 | 26.93M | 16,365,969 | — | ↗ |
| 2022-02-09 | Innoviva, Inc. | Director | P-Purchase | A | Common Stock | 3,614,792 | 5.00 | 18.07M | 10,980,761 | — | ↗ |
| 2021-10-29 | Innoviva, Inc. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,212,122 | 3.30 | 4.00M | 7,365,969 | — | ↗ |
| 2021-08-02 | Varnum Brian | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 3.82 | 477.5K | 125,000 | — | ↗ |
| 2021-06-07 | Schlesinger Sarah J. | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 4.29 | 120.1K | 28,000 | — | ↗ |
| 2021-06-07 | Peterson Todd C. | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 4.29 | 120.1K | 28,000 | — | ↗ |
| 2021-06-07 | PATTI JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 4.29 | 120.1K | 28,000 | — | ↗ |
| 2021-06-07 | Odysseas Kostas D | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 4.29 | 120.1K | 28,000 | — | ↗ |
| 2021-06-07 | Kramer Robin | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 4.29 | 120.1K | 28,000 | — | ↗ |
| 2021-04-01 | Haimovitz Jules | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 4.74 | 142.2K | 30,000 | — | ↗ |
| 2021-03-25 | Varnum Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 112,000 | 5.14 | 575.7K | 112,000 | — | ↗ |
| 2021-03-25 | Patrick Todd | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 112,000 | 5.14 | 575.7K | 112,000 | — | ↗ |
| 2021-03-25 | Morris Duane Alfred | Officer | A-Award | A | Stock Option (Right to Buy) | 28,000 | 5.14 | 143.9K | 28,000 | — | ↗ |
| 2021-03-25 | Martin Steven Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 56,000 | 5.14 | 287.8K | 56,000 | — | ↗ |
| 2021-03-17 | Innoviva, Inc. | Director / 10% Owner | P-Purchase | A | Warrants to Purchase Common Stock | 4,285,935 | 3.25 | 13.93M | 6,153,847 | — | ↗ |
| 2021-01-26 | Innoviva, Inc. | Director / 10% Owner | P-Purchase | A | Warrants to Purchase Common Stock | 1,867,912 | 3.25 | 6.07M | 1,867,912 | — | ↗ |
| 2020-12-08 | Varnum Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Schlesinger Sarah J. | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Peterson Todd C. | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Patrick Todd | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | PATTI JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Odysseas Kostas D | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Morris Duane Alfred | Officer | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Martin Steven Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-12-08 | Kramer Robin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-08 | BASTIANI RICHARD | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 3.15 | 72.5K | 23,000 | — | ↗ |
| 2020-03-27 | Innoviva, Inc. | 10% Owner | P-Purchase | A | Common Stock | 7,717,661 | 2.87 | 22.15M | 8,710,800 | — | ↗ |
| 2020-02-12 | Schlesinger Sarah J. | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 4.17 | 114.2K | 27,383 | — | ↗ |
| 2020-02-12 | Odysseas Kostas D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-12 | Innoviva, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 993,139 | — | ↗ |
| 2019-10-10 | Peterson Todd C. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | Varnum Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 298,724 | 3.15 | 941.0K | 298,724 | — | ↗ |
| 2019-05-22 | Patrick Todd | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 298,724 | 3.15 | 941.0K | 298,724 | — | ↗ |
| 2019-05-22 | PERRY MICHAEL S | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 3.15 | 86.3K | 27,383 | — | ↗ |
| 2019-05-22 | PATTI JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 3.15 | 86.3K | 27,383 | — | ↗ |
| 2019-05-22 | PARKER H STEWART | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 3.15 | 86.3K | 27,383 | — | ↗ |
| 2019-05-22 | Morris Duane Alfred | Officer | A-Award | A | Stock Option (Right to Buy) | 74,681 | 3.15 | 235.2K | 74,681 | — | ↗ |
| 2019-05-22 | Martin Steven Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 149,362 | 3.15 | 470.5K | 149,362 | — | ↗ |
| 2019-05-22 | COOK JEREMY CURNOCK | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 3.15 | 86.3K | 27,383 | — | ↗ |
| 2019-05-22 | Bear Richard | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 3.15 | 86.3K | 27,383 | — | ↗ |
| 2019-05-22 | BASTIANI RICHARD | Director | A-Award | A | Stock Option (Right to Buy) | 27,383 | 3.15 | 86.3K | 27,383 | — | ↗ |
| 2019-05-09 | Varnum Brian | Officer | — | D | Common Stock | 0 | 0.00 | — | 32,162 | — | ↗ |
| 2019-05-09 | Patrick Todd | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 204,086 | — | ↗ |
| 2019-05-09 | PERRY MICHAEL S | Director | J-Other | D | Warrant to Purchase Common Stock | 46,666 | 0.32 | 15.0K | 0 | — | ↗ |
| 2019-05-09 | PATTI JOSEPH M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-09 | PARKER H STEWART | Director | — | D | Common Stock | 0 | 0.00 | — | 13,889 | — | ↗ |
| 2019-05-09 | Morris Duane Alfred | Officer | — | D | Stock Option (Right to Buy) | 7,399 | 38.11 | 282.0K | 0 | — | ↗ |
| 2019-05-09 | Delta Dental of Wisconsin, Inc. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 478,681 | — | ↗ |
| 2019-05-09 | Delta Dental Plan of Michigan, Inc. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,265,802 | — | ↗ |
| 2019-05-09 | COOK JEREMY CURNOCK | Director | J-Other | D | Warrant to Purchase Common Stock | 46,666 | 0.32 | 15.0K | 0 | — | ↗ |
| 2019-05-09 | Bear Richard | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-09 | BASTIANI RICHARD | Director | — | D | Stock Option (Right to Buy) | 809 | 38.11 | 30.8K | 0 | — | ↗ |
| 2018-03-22 | PERRY MICHAEL S | Director | P-Purchase | A | Common Stock | 181,820 | 1.10 | 200.0K | 411,105 | — | ↗ |
| 2018-03-22 | COOK JEREMY CURNOCK | Director | P-Purchase | A | Common Stock | 181,820 | 1.10 | 200.0K | 411,105 | — | ↗ |
| 2017-12-08 | GRINT PAUL C | Director / Officer | A-Award | A | Common Stock | 599 | 0.62 | 371.38 | 599 | — | ↗ |
| 2017-09-19 | PERRY MICHAEL S | Director | P-Purchase | A | Common Stock | 105,015 | 0.00 | — | 229,285 | — | ↗ |
| 2017-09-19 | COOK JEREMY CURNOCK | Director | P-Purchase | A | Common Stock | 105,015 | 0.00 | — | 229,285 | — | ↗ |
| 2017-09-07 | SAMANT VIJAY B | Director | A-Award | A | Stock Option (Right to Buy) | 10,900 | 0.91 | 9.9K | 10,900 | — | ↗ |
| 2017-09-07 | PERRY MICHAEL S | Director | A-Award | A | Stock Option (Right to Buy) | 10,900 | 0.91 | 9.9K | 10,900 | — | ↗ |
| 2017-09-07 | Johnson Wendy S. | Director | A-Award | A | Stock Option (Right to Buy) | 10,900 | 0.91 | 9.9K | 10,900 | — | ↗ |
| 2017-09-07 | GRINT PAUL C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 190,076 | 0.91 | 173.0K | 190,076 | — | ↗ |
| 2017-09-07 | DRAPEAU LOUIS | Director | A-Award | A | Stock Option (Right to Buy) | 10,900 | 0.91 | 9.9K | 10,900 | — | ↗ |
| 2017-09-07 | COOK JEREMY CURNOCK | Director | A-Award | A | Stock Option (Right to Buy) | 10,900 | 0.91 | 9.9K | 10,900 | — | ↗ |
| 2017-06-29 | PERRY MICHAEL S | Director | P-Purchase | A | Common Stock | 5,757 | 0.00 | — | 124,270 | — | ↗ |
| 2017-06-29 | COOK JEREMY CURNOCK | Director | P-Purchase | A | Common Stock | 5,757 | 0.00 | — | 124,270 | — | ↗ |
| 2017-05-30 | BILINSKY IGOR | Officer | A-Award | A | Stock Option (Right to Buy) | 87,161 | 0.74 | 64.5K | 87,161 | — | ↗ |
| 2017-04-01 | Salka Michael Scott | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 214,214 | 0.43 | 92.1K | 214,214 | — | ↗ |
| 2017-04-01 | Martin Steven Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 161,290 | 0.43 | 69.4K | 161,290 | — | ↗ |
| 2017-04-01 | BILINSKY IGOR | Officer | A-Award | A | Stock Option (Right to Buy) | 176,411 | 0.43 | 75.9K | 176,411 | — | ↗ |
| 2017-01-30 | BILINSKY IGOR | Officer | A-Award | A | Stock Option (Right to Buy) | 247,322 | 0.46 | 113.8K | 247,322 | — | ↗ |
| 2016-12-29 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 21,923 | 0.45 | 9.9K | 736,170 | — | ↗ |
| 2016-12-28 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 40,450 | 0.47 | 19.0K | 694,246 | — | ↗ |
| 2016-12-27 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 24,092 | 0.51 | 12.3K | 734,696 | — | ↗ |
| 2016-12-09 | Salka Michael Scott | Director / Officer | A-Award | A | Common Stock | 7,000 | 0.39 | 2.7K | 11,200 | — | ↗ |
| 2016-12-09 | Martin Steven Robert | Officer | A-Award | A | Common Stock | 3,760 | 0.39 | 1.5K | 3,760 | — | ↗ |
| 2016-11-22 | COOK JEREMY CURNOCK | Director | P-Purchase | A | Warrant to Purchase Common Stock | 46,666 | 0.57 | 26.8K | 46,666 | — | ↗ |
| 2016-11-12 | KIRK RANDAL J | 10% Owner | C-Conversion | A | Common Stock | 428,571 | 0.00 | — | 828,571 | — | ↗ |
| 2016-06-21 | COOK JEREMY CURNOCK | Director | P-Purchase | A | Common Stock | 15,057 | 0.00 | — | 71,847 | — | ↗ |
| 2016-04-08 | COOK JEREMY CURNOCK | Director | A-Award | A | Warrant to Purchase Common Stock | 35,714 | 4.05 | 144.6K | 35,714 | — | ↗ |
| 2016-01-18 | Martin Steven Robert | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-11-05 | SAMANT VIJAY B | Director | A-Award | A | Stock Option (Right to Buy) | 16,200 | 5.65 | 91.5K | 16,200 | — | ↗ |
| 2015-11-05 | GRINT PAUL C | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-10-06 | DRAPEAU LOUIS | Director | P-Purchase | A | Common Stock | 10,000 | 4.39 | 43.9K | 10,000 | — | ↗ |
| 2015-10-05 | Salka Michael Scott | Director / Officer | P-Purchase | A | Common Stock | 4,200 | 4.75 | 20.0K | 4,200 | — | ↗ |
| 2015-10-05 | Johnson Wendy S. | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 4.43 | 4.4K | 1,000 | — | ↗ |
| 2015-09-21 | PERRY MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 12,800 | 6.38 | 81.7K | 12,800 | — | ↗ |
| 2015-09-21 | Kirk Julian P. | Director | A-Award | A | Option to Purchase Common Stock | 16,200 | 6.38 | 103.4K | 16,200 | — | ↗ |
| 2015-09-21 | Johnson Wendy S. | Director / Officer | A-Award | A | Stock Option (right to buy) | 16,200 | 6.38 | 103.4K | 16,200 | — | ↗ |
| 2015-09-21 | DRAPEAU LOUIS | Director | A-Award | A | Stock Option (right to buy) | 13,800 | 6.38 | 88.0K | 13,800 | — | ↗ |
| 2015-09-21 | COOK JEREMY CURNOCK | Director | A-Award | A | Stock Option (right to buy) | 38,500 | 6.38 | 245.6K | 38,500 | — | ↗ |
| 2015-08-05 | Salka Michael Scott | Director / Officer | A-Award | A | Stock Option (right to buy) | 19,985,810 | 0.19 | 3.78M | 19,985,810 | — | ↗ |
| 2015-03-16 | KIRK RANDAL J | 10% Owner | P-Purchase | A | Common Stock | 13,939,392 | 0.17 | 2.30M | 37,939,392 | — | ↗ |
| 2015-03-16 | COOK JEREMY CURNOCK | Director | P-Purchase | A | Common Stock | 68,455 | 8.25 | 564.8K | 188,455 | — | ↗ |
| 2014-02-18 | Young Philip J | Director / Officer | — | D | Stock Option (right to buy) | 8,400,000 | 0.20 | 1.68M | 0 | — | ↗ |
| 2014-02-18 | Wendt Kelley A | Officer | — | D | Stock Option (right to buy) | 500,000 | 0.20 | 100.0K | 0 | — | ↗ |
| 2014-02-18 | PERRY MICHAEL S | Director | — | D | Stock Option (right to buy) | 170,000 | 0.20 | 34.0K | 0 | — | ↗ |
| 2014-02-18 | Kirk Julian P. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-02-18 | KIRK RANDAL J | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2014-02-18 | DRAPEAU LOUIS | Director | — | D | Stock Option (right to buy) | 120,000 | 0.20 | 24.0K | 0 | — | ↗ |
| 2014-02-18 | COOK JEREMY CURNOCK | Director | — | D | Stock Option (right to buy) | 440,000 | 0.20 | 88.0K | 0 | — | ↗ |
| 2013-06-26 | WILLIAMS GWYNN | 10% Owner | — | I | Warrant (right to buy) | 8,062,652 | 0.14 | 1.13M | 0 | — | ↗ |
| 2013-06-26 | KIRK RANDAL J | 10% Owner | — | I | Warrant (right to buy) | 5,357,142 | 0.14 | 750.0K | 0 | — | ↗ |
| 2013-05-13 | WILLIAMS GWYNN | 10% Owner | — | I | Warrant (right to buy) | 892,857 | 0.14 | 125.0K | 0 | — | ↗ |
| 2010-05-27 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 70,000 | — | ↗ |
| 2010-05-27 | COOK JEREMY CURNOCK | Director | A-Award | A | Common Stock | 70,000 | 0.00 | — | 100,000 | — | ↗ |
| 2010-04-16 | Robinson BG Susan | Director / Officer | F-InKind | D | Common Stock | 99,187 | 0.22 | 21.8K | 310,814 | — | ↗ |
| 2010-04-16 | Poston David J | Officer | F-InKind | D | Common Stock | 66,125 | 0.22 | 14.5K | 220,576 | — | ↗ |
| 2009-10-12 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 675,000 | 0.26 | 175.8K | 0 | — | ↗ |
| 2009-10-09 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 200,000 | 0.26 | 51.6K | 675,000 | — | ↗ |
| 2009-10-08 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 1,120,481 | 0.26 | 296.6K | 875,000 | — | ↗ |
| 2009-10-07 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 200,000 | 0.30 | 61.0K | 1,995,481 | — | ↗ |
| 2009-09-09 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.50 | 50.1K | 2,255,481 | — | ↗ |
| 2009-06-05 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 900 | 0.50 | 450.00 | 2,355,475 | — | ↗ |
| 2009-06-03 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 145,552 | 0.05 | 6.9K | 2,356,375 | — | ↗ |
| 2009-05-29 | Robinson BG Susan | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 0.27 | 135.0K | 500,000 | — | ↗ |
| 2009-05-29 | Poston David J | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.27 | 67.5K | 250,000 | — | ↗ |
| 2009-05-29 | LEVY NELSON L | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.27 | 16.2K | 60,000 | — | ↗ |
| 2009-05-29 | HAWLEY ROGER | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.27 | 16.2K | 60,000 | — | ↗ |
| 2009-05-29 | DAVIE JOSEPH MD PHD | Director | A-Award | A | Stock option (right to buy) | 60,000 | 0.27 | 16.2K | 60,000 | — | ↗ |
| 2009-05-29 | COOK JEREMY CURNOCK | Director | A-Award | A | Stock Option (right to buy) | 90,000 | 0.27 | 24.3K | 90,000 | — | ↗ |
| 2009-05-17 | Robinson BG Susan | Director / Officer | F-InKind | D | Common Stock | 3,809 | 0.21 | 799.89 | 59,297 | — | ↗ |
| 2009-05-17 | Poston David J | Officer | F-InKind | D | Common Stock | 3,085 | 0.21 | 647.85 | 65,530 | — | ↗ |
| 2009-05-15 | Robinson BG Susan | Director / Officer | F-InKind | D | Common Stock | 3,809 | 0.21 | 799.89 | 63,106 | — | ↗ |
| 2009-05-15 | Poston David J | Officer | F-InKind | D | Common Stock | 3,085 | 0.21 | 647.85 | 68,615 | — | ↗ |
| 2008-11-06 | Robinson BG Susan | Officer | — | D | Stock option (right to buy) | 5,000 | 13.10 | 65.5K | 0 | — | ↗ |
| 2008-06-23 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 399 | 0.67 | 267.33 | 2,501,927 | — | ↗ |
| 2008-05-15 | Poston David J | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 71,700 | — | ↗ |
| 2008-05-15 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2008-05-15 | PARKER H STEWART | Director / Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 131,175 | — | ↗ |
| 2008-05-15 | LEVY NELSON L | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 20,070 | — | ↗ |
| 2008-05-15 | HAWLEY ROGER | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2008-05-15 | DAVIE JOSEPH MD PHD | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 21,000 | — | ↗ |
| 2008-05-15 | COOK JEREMY CURNOCK | Director / Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 30,000 | — | ↗ |
| 2008-05-15 | CARTER BARRIE J PHD | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 83,766 | — | ↗ |
| 2008-04-28 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 8,300 | 0.91 | 7.5K | 2,502,326 | — | ↗ |
| 2008-04-11 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 200 | 0.90 | 180.00 | 2,510,626 | — | ↗ |
| 2008-04-09 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 12,900 | 0.94 | 12.1K | 2,510,826 | — | ↗ |
| 2008-04-08 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 29,100 | 0.93 | 27.2K | 2,523,726 | — | ↗ |
| 2008-04-07 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 26,100 | 0.91 | 23.7K | 2,552,826 | — | ↗ |
| 2008-03-03 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 2,371 | 1.15 | 2.7K | 2,578,926 | — | ↗ |
| 2008-02-06 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | S-Sale | D | Common Stock | 42,800 | 1.15 | 49.2K | 2,581,297 | — | ↗ |
| 2007-07-11 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | — | I | Warrants | 315,000 | 5.41 | 1.70M | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.2K
Shares Outstanding
36.63M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Deborah Birx, M.D. Chief Executive Officer | 562.4K | — | — | 398.0K | 281.2K | 8.3K | 1.25M | 31.84% | ↗ |
| 2 | 2025 | Pierre Kyme, Ph.D. Chief Business Officer | 412.0K | 1.0K | — | 165.8K | 206.0K | 6.8K | 791.6K | 20.95% | ↗ |
| 3 | 2025 | David House Senior Vice President, Finance and | 360.5K | 1.0K | — | 41.5K | 144.2K | 7.6K | 554.8K | 7.47% | ↗ |
| 4 | 2024 | Deborah Birx, M.D. Chief Executive Officer | 546.0K | — | 202.8K | 826.4K | 259.4K | 9.0K | 1.84M | 55.83% | ↗ |
| 5 | 2024 | Mina Pastagia, M.D. Former Chief Medical Officer | 450.9K | 75.0K | 33.8K | — | — | 482.2K | 1.04M | 3.24% | ↗ |
| 6 | 2024 | Pierre Kyme, Ph.D. Chief Business Officer | 379.5K | 75.0K | 33.8K | 137.7K | 190.0K | 7.6K | 823.6K | 20.83% | ↗ |
| 7 | 2024 | Richard Rychlik Former Vice President, Corporate Controller | 243.9K | — | 33.8K | — | — | 82.7K | 360.4K | 9.38% | ↗ |
| 8 | 2024 | David House Senior Vice President, Finance and | 131.3K | — | — | 134.7K | 49.9K | 3.5K | 319.4K | 42.17% | ↗ |
| 9 | 2024 | David House Senior Vice President, Finance and Principal Financial Officer | 131.3K | — | — | 134.7K | — | 3.5K | 269.4K | 49.99% | ↗ |
| 10 | 2023 | Deborah Birx, M.D. Chief Executive Officer | 251.6K | — | 478.0K | 397.5K | — | 6.9K | 1.13M | 77.21% | ↗ |
| 11 | 2023 | Brian Varnum, PhD. Former Chief Executive Officer | 331.0K | — | — | — | — | 555.9K | 634.1K | 0.00% | ↗ |
| 12 | 2023 | Mina Pastagia, M.D. Former Chief Medical Officer | 456.8K | — | — | — | — | 7.0K | 463.8K | 0.00% | ↗ |
| 13 | 2023 | Mina Pastagia, M.D. Chief Medical Officer | 456.8K | — | — | — | — | 7.0K | 463.8K | 0.00% | ↗ |
| 14 | 2023 | Erin Butler Former Vice President, Finance Administration | 131.0K | — | — | — | — | 156.3K | 287.3K | 0.00% | ↗ |
| 15 | 2023 | Richard Rychlik Former Vice President, Corporate Controller | 96.7K | — | — | 99.3K | — | 1.8K | 197.7K | 50.20% | ↗ |
| 16 | 2023 | Richard Rychlik Vice President, Corporate Controller | 96.7K | — | — | 99.3K | — | 1.8K | 197.7K | 50.20% | ↗ |
| 17 | 2022 | Brian Varnum, Ph. D. Chief Executive Officer | 525.0K | 210.0K | — | 904.9K | — | — | 1.64M | 55.18% | ↗ |
| 18 | 2022 | Brian Varnum, PhD. Former Chief Executive Officer | 525.0K | 210.0K | — | 904.9K | — | — | 1.64M | 55.18% | ↗ |
| 19 | 2022 | Mina Pastagia, M.D. Senior Vice President, Clinical Development | 420.0K | 117.6K | — | 301.6K | — | — | 839.2K | 35.94% | ↗ |
| 20 | 2022 | Mina Pastagia, M.D. Chief Medical Officer | 420.0K | 117.6K | — | 301.6K | — | — | 839.2K | 35.94% | ↗ |
| 21 | 2022 | Erin Butler Vice President, Finance & Administration | 275.0K | 66.0K | — | 188.5K | — | — | 529.5K | 35.60% | ↗ |
| 22 | 2022 | Erin Butler Former Vice President, Finance Administration | 275.0K | 66.0K | — | 188.5K | — | — | 529.5K | 35.60% | ↗ |
| 23 | 2022 | Steve Martin Former Chief Financial Officer | 389.3K | — | — | — | — | — | 389.3K | 0.00% | ↗ |
| 24 | 2021 | Brian Varnum, Ph.D. Chief Executive Officer (former President and Chief Development Officer) | 463.7K | — | — | 780.4K | 231.8K | — | 1.48M | 52.88% | ↗ |
| 25 | 2021 | Brian Varnum, Ph. D. Chief Executive Officer | 463.7K | 231.8K | — | 780.4K | — | — | 1.48M | 52.88% | ↗ |
| 26 | 2021 | Todd Patrick Former Chief Executive Officer | 566.5K | — | — | 529.8K | 283.3K | — | 1.38M | 38.40% | ↗ |
| 27 | 2021 | Steve Martin Chief Financial Officer | 370.8K | — | — | 219.9K | 148.3K | — | 739.0K | 29.76% | ↗ |
| 28 | 2021 | Steve Martin Former Chief Financial Officer | 370.8K | 148.3K | — | 135.7K | — | — | 654.8K | 20.72% | ↗ |
| 29 | 2020 | Todd Patrick Chief Executive Officer | 515.5K | — | — | 53.5K | 257.8K | — | 826.8K | 6.47% | ↗ |
| 30 | 2020 | Todd Patrick Former Chief Executive Officer | 515.5K | — | — | 53.5K | 257.8K | — | 826.8K | 6.47% | ↗ |
| 31 | 2020 | Brian Varnum, Ph.D. Chief Executive Officer (former President and Chief Development Officer) | 398.8K | — | — | 53.5K | 159.5K | — | 611.8K | 8.75% | ↗ |
| 32 | 2020 | Brian Varnum, Ph. D. President and Chief Development Officer | 398.8K | — | — | 53.5K | 159.5K | — | 611.8K | 8.75% | ↗ |
| 33 | 2020 | Steve Martin Senior VP and Chief Financial Officer | 350.0K | — | — | 53.5K | 140.0K | — | 543.5K | 9.84% | ↗ |
| 34 | 2020 | Steve Martin Chief Financial Officer | 350.0K | — | — | 53.5K | 140.0K | — | 543.5K | 9.84% | ↗ |
| 35 | 2019 | Todd Patrick Chief Executive Officer | 412.0K | — | — | 714.6K | 144.2K | — | 1.27M | 56.23% | ↗ |
| 36 | 2019 | Brian Varnum, Ph. D. President and Chief Development Officer | 320.0K | — | — | 714.6K | 89.6K | — | 1.12M | 63.56% | ↗ |
| 37 | 2019 | Steve Martin Senior VP and Chief Financial Officer | 320.0K | — | — | 357.3K | 89.6K | — | 766.9K | 46.59% | ↗ |
| 38 | 2019 | Paul C. Grint, M.D. Former Chief Executive Officer | 170.9K | — | — | 4.1K | — | 519.7K | 694.8K | 0.59% | ↗ |
| 39 | 2018 | Todd Patrick Chief Executive Officer | 412.0K | — | — | — | 206.0K | — | 618.0K | 0.00% | ↗ |
| 40 | 2018 | Paul C. Grint, M.D. Former Chief Executive Officer | 475.0K | — | — | — | 143.0K | — | 618.0K | 0.00% | ↗ |
| 41 | 2018 | Brian Varnum, Ph. D. President and Chief Development Officer | 320.0K | — | — | — | 128.0K | — | 448.0K | 0.00% | ↗ |
| 42 | 2018 | Steve Martin Senior VP and Chief Financial Officer | 320.0K | — | — | — | 109.0K | — | 429.0K | 0.00% | ↗ |
| 43 | 2018 | Igor P. Bilinsky, Ph.D. Former Senior VP and Chief Operating Officer | 350.0K | — | — | — | — | — | 350.0K | 0.00% | ↗ |
| 44 | 2017 | Igor P. Bilinsky, Ph.D. Former Senior VP and Chief Operating Officer | 323.5K | — | — | 201.2K | 183.8K | — | 708.5K | 28.39% | ↗ |
| 45 | 2017 | Dr. Igor Bilinsky, Senior VP and Chief Operating Officer | 323.5K | — | — | 201.2K | 183.8K | — | 708.5K | 28.39% | ↗ |
| 46 | 2017 | Michael Scott Salka, former Chief Executive Officer | 227.8K | — | — | 84.7K | 144.1K | 247.9K | 704.4K | 12.02% | ↗ |
| 47 | 2017 | Steve Martin Senior VP and Chief Financial Officer | 320.0K | — | — | 154.1K | 173.4K | — | 647.5K | 23.80% | ↗ |
| 48 | 2017 | Steve Martin, Senior VP and Chief Financial Officer | 320.0K | — | — | 154.1K | 173.4K | — | 647.5K | 23.80% | ↗ |
| 49 | 2017 | Paul C. Grint, M.D. Former Chief Executive Officer | 277.1K | — | — | 154.2K | 50.0K | 18.8K | 500.0K | 30.83% | ↗ |
| 50 | 2017 | Dr. Paul Grint, Chief Executive Officer | 277.1K | — | — | 154.2K | 50.0K | 18.8K | 500.0K | 30.83% | ↗ |
| 51 | 2016 | Steve Martin, Senior VP and Chief Financial Officer | 306.7K | — | — | 239.8K | 67.2K | 1.3K | 615.0K | 38.99% | ↗ |
| 52 | 2016 | Wendy S. Johnson, Interim Chief Operating Officer and Director | 300.0K | — | — | — | 250.0K | 40.0K | 590.0K | 0.00% | ↗ |
| 53 | 2016 | Michael Scott Salka, former Chief Executive Officer | 425.0K | — | — | — | 102.0K | 988.00 | 528.0K | 0.00% | ↗ |
| 54 | 2016 | Michael Scott Salka, Chief Executive Officer | 425.0K | — | — | — | 102.0K | 988.00 | 528.0K | 0.00% | ↗ |
| 55 | 2016 | Dr. Paul Grint, Chief Executive Officer | — | — | — | — | — | 45.0K | 45.0K | 0.00% | ↗ |
| 56 | 2015 | Michael Scott Salka, Chief Executive Officer | 264.3K | — | — | 3.47M | 85.0K | 364.00 | 3.82M | 90.85% | ↗ |
| 57 | 2015 | Wendy S. Johnson, Interim Chief Operating Officer and Director | 270.0K | 25.0K | — | 289.4K | — | 30.0K | 614.4K | 47.10% | ↗ |
| 58 | 2015 | Jeremy Curnock Cook, Former Interim Chief Executive Officer and President and Current Chairman of our Board of Directors | — | 100.0K | — | 223.9K | — | 58.3K | 382.2K | 58.59% | ↗ |
| 59 | 2015 | David E. Bosher, Former Interim Chief Financial Officer | 308.7K | — | — | — | — | — | 308.7K | 0.00% | ↗ |
| 60 | 2014 | Philip J. Young Former President, Chief Executive Officer and Director | 294.7K | 240.0K | — | — | — | 1.91M | 2.44M | 0.00% | ↗ |
| 61 | 2014 | Kelley A. Wendt, Chief Financial Officer | 158.9K | — | — | — | — | — | 158.9K | 0.00% | ↗ |
| 62 | 2014 | David E. Bosher, Interim Chief Financial Officer | 127.1K | — | — | — | — | — | 127.1K | 0.00% | ↗ |
| 63 | 2014 | David E. Bosher, Former Interim Chief Financial Officer | 127.1K | — | — | — | — | — | 127.1K | 0.00% | ↗ |
| 64 | 2014 | Wendy S. Johnson, Interim Chief Operating Officer and Director | 60.0K | — | — | — | — | 7.3K | 67.3K | 0.00% | ↗ |
| 65 | 2014 | Wendy S. Johnson, Interim Chief Operating Officer | 60.0K | — | — | — | — | 7.3K | 67.3K | 0.00% | ↗ |
| 66 | 2014 | Jeremy Curnock Cook, Former Interim Chief Executive Officer and President and Current Chairman of our Board of Directors | — | — | — | — | — | 50.3K | 50.3K | 0.00% | ↗ |
| 67 | 2014 | Jeremy Curnock Cook, Interim Chief Executive Officer | — | — | — | — | — | 50.3K | 50.3K | 0.00% | ↗ |
| 68 | 2013 | Philip J. Young President and CEO and Director | 400.0K | — | — | 1.86M | — | 105.4K | 2.36M | 78.60% | ↗ |
| 69 | 2013 | Philip J. Young Former President, Chief Executive Officer and Director | 400.0K | — | — | 1.86M | — | 105.4K | 2.36M | 78.60% | ↗ |
| 70 | 2013 | David Harper, Ph.D. Chief Scientific Officer | 225.5K | — | — | — | — | — | 225.5K | 0.00% | ↗ |
| 71 | 2013 | Kelley A. Wendt, Chief Financial Officer | 155.9K | — | — | — | — | 18.6K | 174.5K | 0.00% | ↗ |
| 72 | 2013 | Kelley A. Wendt Chief Financial Officer | 155.9K | — | — | — | — | 18.6K | 174.5K | 0.00% | ↗ |
| 73 | 2012 | Philip J. Young President and CEO and Director | 325.0K | — | — | 1.68M | — | — | 2.01M | 83.79% | ↗ |
| 74 | 2012 | David Harper, Ph.D. Chief Scientific Officer | 228.7K | — | — | 240.0K | — | — | 468.7K | 51.21% | ↗ |
| 75 | 2012 | Kelley A. Wendt Chief Financial Officer | — | — | — | 100.0K | — | 120.2K | 220.2K | 45.40% | ↗ |
| 76 | 2008 | H. Stewart Parker Former President and Chief Executive Officer | 374.0K | — | 75.8K | — | — | 47.7K | 497.5K | 15.23% | ↗ |
| 77 | 2008 | Barrie J. Carter, Ph.D. Former Executive Vice President and Chief Scientific Officer | 246.5K | — | 42.3K | — | — | 36.4K | 325.2K | 13.00% | ↗ |
| 78 | 2008 | David J. Poston Vice President, Finance, Chief Financial Officer, Treasurer and Secretary | 257.5K | — | 42.3K | — | — | 2.4K | 302.2K | 13.99% | ↗ |
| 79 | 2008 | B.G. Susan Robinson President and Chief Executive Officer | 257.5K | — | 42.3K | — | — | 2.4K | 302.2K | 13.99% | ↗ |
| 80 | 2007 | H. Stewart Parker Former President and Chief Executive Officer | 440.0K | 154.0K | 32.7K | 29.1K | — | 4.4K | 660.2K | 9.36% | ↗ |
| 81 | 2007 | H. Stewart Parker President and Chief Executive Officer | 440.0K | 154.0K | 32.7K | 29.1K | — | 4.4K | 660.2K | 9.36% | ↗ |
| 82 | 2007 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 290.0K | 72.5K | 22.9K | 23.0K | — | 3.9K | 412.3K | 11.12% | ↗ |
| 83 | 2007 | Barrie J. Carter, Ph.D. Former Executive Vice President and Chief Scientific Officer | 290.0K | 72.5K | 22.9K | 23.0K | — | 3.9K | 412.3K | 11.12% | ↗ |
| 84 | 2007 | David J. Poston Vice President, Finance, Chief Financial Officer, Treasurer and Secretary | 250.0K | 50.0K | 22.9K | 23.0K | — | 2.2K | 348.1K | 13.17% | ↗ |
| 85 | 2007 | David J. Poston Vice President, Finance, Chief Financial Officer and Treasurer | 250.0K | 50.0K | 22.9K | 23.0K | — | 2.2K | 348.1K | 13.17% | ↗ |
| 86 | 2007 | B.G. Susan Robinson President and Chief Executive Officer | 250.0K | 50.0K | 22.9K | 19.0K | — | 2.4K | 344.2K | 12.16% | ↗ |
| 87 | 2006 | H. Stewart Parker President and Chief Executive Officer | 418.0K | 62.7K | — | 36.0K | — | 3.5K | 520.2K | 6.92% | ↗ |
| 88 | 2006 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 278.0K | 41.7K | — | 28.5K | — | 2.5K | 350.7K | 8.12% | ↗ |
| 89 | 2006 | David J. Poston Vice President, Finance, Chief Financial Officer and Treasurer | 200.0K | 30.0K | — | 28.5K | — | 951.00 | 259.4K | 10.97% | ↗ |
| 90 | 2005 | H. Stewart Parker President and Chief Executive Officer | 418.0K | — | — | — | — | 4.5K | 422.5K | 0.00% | ↗ |
| 91 | 2005 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 278.0K | — | — | — | — | — | 278.0K | 0.00% | ↗ |
| 92 | 2005 | Todd E. Simpson Former Vice President, Finance and Administration, Chief | 211.4K | — | — | — | — | 45.8K | 257.2K | 0.00% | ↗ |
| 93 | 2005 | David J. Poston Vice President, Finance, Chief Financial Officer and Treasurer | 150.5K | — | — | — | — | 3.7K | 154.2K | 0.00% | ↗ |
| 94 | 2004 | H. Stewart Parker President and Chief Executive Officer | 398.0K | 82.0K | — | — | — | 3.9K | 483.8K | 0.00% | ↗ |
| 95 | 2004 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 265.0K | 39.0K | — | — | — | 5.0K | 308.9K | 0.00% | ↗ |
| 96 | 2004 | Todd E. Simpson Former Vice President, Finance and Administration, Chief | 240.0K | 35.3K | — | — | — | 26.5K | 301.8K | 0.00% | ↗ |
| 97 | 2004 | Todd E. Simpson Vice President, Finance and Administration, Chief Financial | 240.0K | 35.3K | — | — | — | 26.5K | 301.8K | 0.00% | ↗ |
| 98 | 2003 | H. Stewart Parker President and Chief Executive Officer | 364.0K | 191.1K | — | — | — | 565.00 | 555.7K | 0.00% | ↗ |
| 99 | 2003 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 243.3K | 90.9K | — | — | — | 1.5K | 335.7K | 0.00% | ↗ |
| 100 | 2003 | Todd E. Simpson Vice President, Finance and Administration, Chief Financial | 210.0K | 78.8K | — | — | — | 24.2K | 312.9K | 0.00% | ↗ |
| 101 | 2003 | Todd E. Simpson Former Vice President, Finance and Administration, Chief | 210.0K | 78.8K | — | — | — | 24.2K | 312.9K | 0.00% | ↗ |
| 102 | 2002 | H. Stewart Parker President and Chief Executive Officer | 364.0K | — | — | — | — | 3.3K | 367.3K | 0.00% | ↗ |
| 103 | 2002 | Todd E. Simpson Vice President, Finance and Administration, Chief Financial | 210.0K | — | — | — | — | 103.4K | 313.4K | 0.00% | ↗ |
| 104 | 2002 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 243.3K | — | — | — | — | 3.7K | 247.0K | 0.00% | ↗ |
| 105 | 2001 | H. Stewart Parker President and Chief Executive Officer | 350.0K | 88.2K | — | — | — | 3.2K | 441.4K | 0.00% | ↗ |
| 106 | 2001 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 233.0K | 34.0K | — | — | — | 3.6K | 270.6K | 0.00% | ↗ |
| 107 | 2001 | Todd E. Simpson Vice President, Finance and Administration, Chief Financial | 52.5K | 6.8K | — | — | — | 15.6K | 74.9K | 0.00% | ↗ |
| 108 | 2000 | Barrie J. Carter, Ph.D. Executive Vice President and Chief Scientific Officer | 194.3K | 103.0K | — | 21.6K | — | 3.2K | 300.4K | 7.19% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deborah L. Birx | Chief Executive Officer & Director | 851.9K | — |
| Pierre Kyme | Chief Business Officer | 625.8K | — |
| David House | Senior Vice President of Finance & Principal Financial Officer | 513.3K | male |
| Bani Tchekanova | Head of Regulatory Strategy & Operations | — | female |
| Peter Hubbard | Vice President of Operations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARMP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
